Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hangzhou Tigermed Consulting Co's quarterly Beginning Cash Position
increased
from Dec. 2025 (HK$1,767 Mil) to Mar. 2026 (HK$1,956 Mil) and
increased
from Mar. 2026 (HK$1,956 Mil) to Jun. 2026 (HK$2,415 Mil).
Hangzhou Tigermed Consulting Co's annual Beginning Cash Position
declined
from Dec. 2023 (HK$8,513 Mil) to Dec. 2024 (HK$7,901 Mil) and
declined
from Dec. 2024 (HK$7,901 Mil) to Dec. 2025 (HK$2,263 Mil).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hangzhou Tigermed Consulting Co Beginning Cash Position Chart
What does a Beginning Cash Position of HK$2,415 Mil mean?
Hangzhou Tigermed Consulting Co (HKSE:03347) has a Beginning Cash Position of HK$2,415 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Hangzhou Tigermed Consulting Co and its competitors.
Is Hangzhou Tigermed Consulting Co's Beginning Cash Position too high?
Hangzhou Tigermed Consulting Co's current Beginning Cash Position is HK$2,415 Mil. Overall, Hangzhou Tigermed Consulting Co has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Hangzhou Tigermed Consulting Co's Beginning Cash Position compare to TMO and DHR?
Hangzhou Tigermed Consulting Co's Beginning Cash Position of HK$2,415 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Medical Diagnostics & Research company?
A good Beginning Cash Position depends on the Medical Diagnostics & Research industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Hangzhou Tigermed Consulting Co and its competitors. Hangzhou Tigermed Consulting Co's current Beginning Cash Position is HK$2,415 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hangzhou Tigermed Consulting Co stock overvalued right now?
Based on GuruFocus' analysis, Hangzhou Tigermed Consulting Co (HKSE:03347) is currently considered Fairly Valued. The stock's GF Value™ is HK$42.57, compared to a current price of HK$44.58 — trading 4.7% above its estimated fair value. The current Beginning Cash Position is HK$2,415 Mil. Hangzhou Tigermed Consulting Co's overall GF Score™ is 91/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Hangzhou Tigermed Consulting Co (HKSE:03347), the current Beginning Cash Position is HK$2,415 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hangzhou Tigermed Consulting Co (HKSE:03347) Overvalued in 2026?
Based on GuruFocus' analysis, Hangzhou Tigermed Consulting Co stock appears to be overvalued.
The current stock price of HK$44.58 is trading 4.7% above its estimated GF Value™ of HK$42.57.
GuruFocus considers Hangzhou Tigermed Consulting Co to be Fairly Valued.
Key valuation signals for HKSE:03347:
Beginning Cash Position: HK$2,415 Mil
GF Value™: HK$42.57 vs. price of HK$44.58 (4.7% above fair value)
No single metric tells the full story. See the HKSE:03347 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hangzhou Tigermed Consulting Co Ltd is a China-based provider of comprehensive biopharmaceutical R&D services, with an expanding world-wide presence. The Group is principally engaged in CRO services.
91GF Score
Get the complete analysis for HKSE:03347
Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:03347 has been successfully added to your 
